6. パーキンソン病
[臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-008210-38-FR
(EUCTR)
16/04/200919/03/2009Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: freezing of gait and glutamate: FOGG-I” - FOGG-IEffet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: freezing of gait and glutamate: FOGG-I” - FOGG-I Patients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease
MedDRA version: 9.1;Level: PT;Term: Parkinson's disease
Trade Name: EBIXA®
Product Name: mémantine
Trade Name: L-Dopa/ MODOPAR
Product Name: L-Dopa
Chru de LilleNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
28France
2EUCTR2005-002038-36-GR
(EUCTR)
27/02/200709/10/2006A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy Bodies
MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
3EUCTR2005-002038-36-FR
(EUCTR)
01/12/200624/08/2010A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy BodiesTrade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
4EUCTR2005-002038-36-DE
(EUCTR)
29/11/200619/01/2007A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy BodiesTrade Name: Ebixa
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLNot RecruitingFemale: yes
Male: yes
200United Kingdom;Germany;France;Spain;Italy;Greece;Austria
5EUCTR2005-002038-36-AT
(EUCTR)
22/09/200609/10/2006A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy BodiesTrade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLNot RecruitingFemale: yes
Male: yes
200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2005-004109-27-SE
(EUCTR)
24/03/200624/01/2006A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDDA double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDD Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder.Trade Name: Ebixa
Product Name: Ebixa
Neuropsychiatric clinicNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Sweden
7EUCTR2004-004139-74-DK
(EUCTR)
20/04/200522/03/2005Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/AParkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A Parkinson's DiseaseTrade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: memantine
Neurologisk afdeling FNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2Denmark